Novo-Nordisk-AR-2012-en

ACCOMPLISHMENTS ACCOMPLISHMENTS AND RESULTS 2012 5
2008 2009 2010 2011 2012 2011–2012
Social performance Change
Patients:
Least developed countries where Novo Nordisk sells
insulin according to the differential pricing policy 32 36 33 36 35 (3%)
Healthcare professionals trained or educated
in diabetes (1,000) N/A 425 373 835 1,274 53%
People with diabetes trained (1,000) N/A 416 494 626 836 34%
Donations (DKK million) 78 83 84 81 84 4%
New patent families (fi rst fi lings) 71 55 62 80 65 (19%)
Employees:
Employees (total) 27,068 29,329 30,483 32,632 34,731 6%
Employees (average FTEs) 26,069 27,985 29,423 31,499 33,061 5%
Employee turnover 12.1% 8.3% 9.1% 9.8% 9.1%
Assurance:
Relevant employees trained in business ethics N/A N/A 98% 99% 99%
Business ethics assurance activities 25 30 35 46 48 4%
Fulfi lment of action points from facilitations
of the Novo Nordisk Way 92% 93% 93% 93% 94%
Product recalls 2 2 5 5 6 20%
Warning Letters and re-inspections 0 0 0 0 1 –
Company reputation with external
key stakeholders (scale 1–7) N/A N/A N/A 5.6 5.7 2%
Long-term social targets Targets
Patients reached with diabetes care
products (million) (estimate) 4 N/A N/A N/A 21 23 40 million by 2020
Working the Novo Nordisk Way
(employee assessment) (scale 1–5) N/A N/A N/A 4.3 4.3 4.0
Diverse senior management teams 5 43% 50% 54% 62% 66% 100% by 2014
Environmental performance Change
Resources:
Energy consumption (1,000 GJ) 2,533 2,246 2,234 2,187 2,433 11%
Water consumption (1,000 m 3 ) 2,684 2,149 2,047 2,136 2,475 16%
Emissions and waste:
CO2 emissions from energy consumption (1,000 tons) 217 166 95 94 122 30%
Wastewater (1,000 m3 ) 2,542 2,062 1,935 2,036 2,272 12%
Waste (tons) 24,314 26,362 25,627 41,376 82,802 100%
Long-term environmental targets
Energy consumption
Targets
(change compared with prior year) (9%) (11%) (1%) (2%) 11% 3% annual growth6 Water consumption
(change compared with prior year) (17%) (20%) (5%) 4% 16% 5% annual growth6 CO2 emissions from energy consumption 10% reduction
(change compared with 2004) 7 (1%) (24%) (56%) (57%) (44%) by 2014
Share performance Change
Basic earnings per share/ADR in DKK 1 15.66 17.97 24.81 30.24 39.09 29%
Diluted earnings per share/ADR in DKK 1 15.54 17.82 24.60 29.99 38.85 30%
Dividend per share in DKK 6.00 7.50 10.00 14.00 18.00 29%
Total dividend (DKK million) 3,650 4,400 5,700 7,742 9,715 8 25%
1. For defi nitions, please refer to p 93.
2. Impact of Zymogenetics, Inc. share divestment, discontinuation of all pulmonary diabetes projects and impact of DAKO A/S share divestment.
3. The long-term fi nancial targets were updated in February 2013. Please refer to p 10.
4. The accounting policy has been updated in line with WHO defi nition, and historical data have been restated accordingly. Please refer to p 97.
5. By the end of 2014 all senior management teams must comply with the target to be diverse in terms of both gender and nationality or explain why this is not achievable.
6. For target defi nition, please refer to p 14.
7. The accounting policy has been updated and historical data have been restated accordingly. The target remains unchanged. Please refer to p 102.
8. Proposed dividend for the year (not yet declared).
NOVO NOVO NORDISK ANNUAL REPORT 2012